Bruce J. Seeley - 30 Jun 2021 Form 4 Insider Report for CTI BIOPHARMA CORP

Reporting relationship: EVP, Chief Operating Officer
Issuer ticker: N/A
Reported as of: 30 Jun 2021
Net transaction value: +$13,556
SEC form: 4
Accepted by SEC: 11 Mar 2022, 18:40:31 UTC
Source filing: View source filing
Reporting owner signature: /s/ Bruce J. Seeley

Key filing fact

Bruce J. Seeley filed Form 4 for CTI BIOPHARMA CORP on 11 Mar 2022.

Key facts

This page summarizes Bruce J. Seeley's Form 4 filing for CTI BIOPHARMA CORP.
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Mar 2022, 18:40.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$13,556.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTIC transaction

Common Stock

Award

Transaction value: $6,724
Shares: +3,164
Change %: +8.4%
Price: $2.12^*
Shares after: 40,664
Date: 30 Jun 2021
Ownership: Direct
Footnotes: F1

CTIC transaction

Common Stock

Award

Transaction value: $6,832
Shares: +3,241
Change %: +8%
Price: $2.11^*
Shares after: 43,905
Date: 31 Dec 2021
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTIC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +280,000
Change %
Price: $0.000000
Shares after: 280,000
Date: 09 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 280,000
Exercise price: $4.49
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.

Footnote F2

The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates.